Skip to content

Evaluation of cytology-based tumor resection for the surgical treatment of head and neck squamous cell carcinoma (HNSCC) patients

Evaluation of cytology-based tumor resection for the surgical treatment of head and neck squamous cell carcinoma (HNSCC) patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013507
Enrollment
50
Registered
2017-12-01
Start date
2017-12-18
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C06.9 C10.9

Interventions

Group 1: Cytological tumor swab in an outpatient setting
if cytology shows a positive finding (tumor cells), a panendoscopy + rapid section histology will be performed
if rapid section histology is positive, a transoral tumor resection in the same operation will be performed (intervention arm) Group 2: Confirmation of clinical diagnosis by panendoscopy + biopsy
transoral tumor resection in a second operation if histology is positive (control arm)

Sponsors

Universitätsklinikum des SaarlandesKlinik für HNO-Heilkunde
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: cT1-2 squamous cell carcinoma of the oral cavity or the oropharynx (tonsil, base of tongue, soft palate); swab cytology feasible in an outpatient setting; planned surgical treatment; no necessarity of a plastic defect coverage by a free or pedicled flap transplant; signed informed consent; Age of 18 years or higher and unlimited legal capacity

Exclusion criteria

Exclusion criteria: Primary tumor in a region outside of the oral cavity or oropharynx; cT3 or higher staged Tumors; no clinical evidence for a malignant disease; swab cytology not feasible in an outpatient setting; no planned surgical treatment; necessarity of a plastic defect coverage with a free or pedicled flap transplant; lack of signed informed consent; age < 18 years or limited legal capacity; pregnancy

Design outcomes

Primary

MeasureTime frame
time span between clinical diagnosis and definitive surgical treatment

Secondary

MeasureTime frame
Overall survival, progression free survival (5 years follow-up), whole time span of treament, diagnostic sensitivity of liquid-based cytology for the diagnosis of HNSCC

Countries

Germany, Luxembourg

Contacts

Public ContactMaximilian Linxweiler

Universitätsklinikum des SaarlandesKlinik für HNO-Heilkunde

maximilian.linxweiler@uks.eu+496841-1622984

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026